Reuters logo
BRIEF-Pfizer presents results from Phase 2 study of investigational ALK-inhibitor lorlatinib
October 16, 2017 / 11:31 AM / a month ago

BRIEF-Pfizer presents results from Phase 2 study of investigational ALK-inhibitor lorlatinib

Oct 16 (Reuters) - Pfizer Inc

* Pfizer presents full results from Phase 2 study of next-generation investigational ALK-inhibitor lorlatinib in ALK-positive and ROS1-positive advanced non-small cell lung cancer

* Pfizer Inc - ‍lorlatinib exhibited clinically meaningful activity against lung tumors and brain metastases in a range of patients enrolled in study

* Pfizer Inc - ‍in study, side effects were generally manageable and primarily mild to moderate in severity​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below